Clinical trial
Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance
NCT05461430 is registered in ClinicalTrials.gov with Travera Inc as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance
- Lead sponsor
- Travera Inc
- Phase
- Observational
- Overall status
- Completed
- Start date
- July 15, 2022
- Completion date
- March 23, 2026
- Enrollment
- 72 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
ascites, malignant, carcinoma, carcinoma bladder, carcinoma breast, carcinoma of esophagus, carcinoma of the anus, carcinoma of the appendix, carcinoma of the bladder, carcinoma of the cervix, carcinoma of the head and neck, carcinoma of the larynx, carcinoma of the nasopharynx, carcinoma of the oral cavity, carcinoma of the oropharynx, carcinoma of the penis, carcinoma of the vulva, carcinoma of unknown primary, carcinoma, hepatocellular, carcinoma, neuroendocrine, carcinoma, non-small-cell lung, carcinoma, ovarian, carcinoma, pancreatic, carcinoma, pancreatic ductal, carcinoma, renal, carcinoma, renal cell, carcinoma, small cell, carcinoma, thymic, cholangiocarcinoma, melanoma, mesothelioma, pancreatic cancer, pleural effusion, malignant